Rabeprazole Sodium Market Analysis and Forecast to 2032: By Application (Gastroesophageal Reflux Disease, Peptic Ulcer, Others), Age (Below 55 Years, Above 55 Years), Distribution Channel (Hospital Pharmacies, Drug & Retail Store Pharmacies, Online Provid

Rabeprazole Sodium Market Analysis and Forecast to 2032: By Application (Gastroesophageal Reflux Disease, Peptic Ulcer, Others), Age (Below 55 Years, Above 55 Years), Distribution Channel (Hospital Pharmacies, Drug & Retail Store Pharmacies, Online Providers), and Region

The global rabeprazole sodium market was valued at USD 615.7 billion in 2022 and it is anticipated to grow further till USD 984 million by 2032, at a CAGR of 4.8% during the forecast period.

Rabeprazole is used to treat duodenal ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD). In addition, it can be used in conjunction with medications to treat ulcers caused by H. pylori bacterial infections (such as amoxicillin and clarithromycin). Rabeprazole, a proton pump inhibitor (PPI), lessens the amount of stomach acid produced. It inhibits the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatas) at the secretory surface of the gastric parietal cell.
Global Rabeprazole Sodium Market Scope and Report Structure
Market Trends and Drivers
Rabeprazole lessens the quantity of stomach acid production. It is frequently used to treat gastroesophageal reflux disease, acid reflux, and heartburn. Acid reflux that occurs repeatedly is known as GORD. Rabeprazole can also be used to treat and prevent stomach ulcers. Therefore, the market is growing as digestive issues become more common. GORD is one of the most prevalent gastrointestinal illnesses, affecting 20% of individuals in western societies, according to the National Library of Medicine. According to El-Serag et alsystematic .'s review, GERD prevalence in the US ranges from 18.1% to 27.8%. Therefore, the industry for rabeprazole sodium is driven by the rise in digestive system problems.
Market Restraints and Challenges
The pipeline products with market players is anticipated to hinder the growth of the market.

Global Rabeprazole Sodium Market Segmental Overview
The global rabeprazole sodium market is segmented into application, age, distribution channel, and region.

Global Rabeprazole Sodium Market by Application

Based on the application, it is segmented into gastroesophageal reflux disease, peptic ulcer, and others. The gastroesophageal reflux disease segment is anticipated to dominate the market during the forecast period. Similarly, the peptic ulcer segment is anticipated to witness the fastest growth during the forecast period.

Global Rabeprazole Sodium Market by Age

Based on the age, it is segmented into below 55 years, and above 55 years. The above 55 years segment is anticipated to dominate the market during the forecast period. Similarly, the below 55 years segment is anticipated to witness the fastest growth during the forecast period.

Global Rabeprazole Sodium Market by Distribution Channel

Based on the distribution channel, it is segmented into hospital pharmacies, drug & retail store pharmacies, and online providers. The hospital pharmacies segment is anticipated to dominate the market during the forecast period. Similarly, the drug & retail store pharmacies segment is anticipated to witness the fastest growth during the forecast period.
Geographical Analysis of the Global Rabeprazole Sodium Market

Region-wise, it is studied across the North America, Europe, Asia Pacific, and the Rest of the World. The North American region is anticipated to dominate the market during the forecast period. Similarly, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period.
Major Players in the Global Rabeprazole Sodium Market
The key players studied the report are Cipla Ltd, Cadila Pharmaceuticals Ltd, Alembic Pharmaceuticals Ltd, Woodward Pharma, Elikem Pharmaceuticals Pvt Ltd, Sun Pharmaceutical Industries Ltd., Jasco Labs Private Limited, Torrent Pharmaceuticals Ltd, Intas Pharmaceutical, Ltd., Dr. Reddy's Laboratories Ltd among others.
COVID-19 Impact
Worldwide, the COVID-19 pandemic has had an impact on healthcare industry workflows. Many sectors of the economy, including some in the health care industry, have been forced to temporarily close their doors because to the sickness. Vaccination currently reduces or prevents morbidity and mortality, but COVID-appropriate social behaviour and test, track, isolate, and treat are still necessary public health treatments. The global rabeprazole sodium market is expected to suffer as a result of the COVID-19 epidemic. Additionally, the lockout caused delays in the production and delivery of crucial medical supplies.
Recent Developments

November 2021, AcipHex delayed-release tablets were acquired from Eisai Co., Ltd. by Woodward Pharma, a specialised pharmaceutical firm with headquarters in Michigan with a focus on purchasing, licensing, and commercializing branded and generic pharmaceuticals for the American market. In accordance Woodward has rights to sell AcipHex in the U.S.

Frequently Asked Questions
Q1. How big is the Rabeprazole Sodium market?

Ans. The global Rabeprazole Sodium market size was USD 615.7 billion in 2022 and it is anticipated to grow further till USD 984 million by 2032, at a CAGR of 4.8% from 2023 to 2032.

Q2. What is the Rabeprazole Sodium market growth rate?

Ans. The growth rate of the Rabeprazole Sodium market is 4.8%.

Q3. Which region holds a major market share for the Rabeprazole Sodium market?

Ans. North America holds a major market share of the Rabeprazole Sodium market in 2022.

Q4. Which segment accounted for the largest Rabeprazole Sodium market share?

Ans. By distribution channel, the hospital pharmacies segment accounted for the largest Rabeprazole Sodium market share.

Q5. Who are the key players in the Rabeprazole Sodium market?

Ans. The global Rabeprazole Sodium market report includes players such as Cipla Ltd, Cadila Pharmaceuticals Ltd, Alembic Pharmaceuticals Ltd, Woodward Pharma, Elikem Pharmaceuticals Pvt Ltd, Sun Pharmaceutical Industries Ltd., Jasco Labs Private Limited, Torrent Pharmaceuticals Ltd, Intas Pharmaceutical, Ltd., Dr. Reddy's Laboratories Ltd among others.

Q6. What are the factors driving the Rabeprazole Sodium market growth?

Ans. The major factors driving the growth of the market are the growing market in emerging countries.

Q7. What are the key growth strategies of Rabeprazole Sodium market players?

Ans. The key growth strategies of Rabeprazole Sodium market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Rabeprazole Sodium market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the Rabeprazole Sodium market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.